Responses to the US Food and Drug Administration's request for comment about its dietary supplement manufacturing and marketing oversight are targeting more than potential regulatory changes.
More than half the 73 comments posted to to the FDA's "Responsible Innovation in Dietary Supplements" docket by the 15 July deadline are from consumers with the same concerns shared by most industry stakeholders – about businesses marketing products
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?